The agreement with Pfizer has not yet been officially signed, and this will be the world’s largest single transaction for Covid-19 vaccines to date. European Commission President Ursula von der Lein announced a landmark purchase during a visit to Pfizer’s Pfizer manufacturing plant in Belgium on Friday, stating that the vaccine will be delivered until 2023.
The reason for the announcement of this agreement is that developed countries are under increasing pressure to stop purchasing more than their population to ensure adequate doses elsewhere in the world.
In an interview with The New York Times, Burla explained: “There are many leaders in the world who will contact me from the president, prime minister, king, and general secretaries of various organizations.” He explained that this kind of dialogue is not rare.
Von der Leyen described the difficulties she faced as a leader because it was clear that AstraZeneca would not achieve its goals.
She said: “I know that the increase in deliveries is essentially a slow start from the beginning, so I also know that the first quarter will be very difficult.”
“I didn’t expect it to be so difficult because we did not consider the possibility of AstraZeneca reducing deliveries by 75%. This is a serious setback.”
According to the “New York Times” report, Von Delane said that the transaction with Pfizer will include the initial 900 million doses and the option of 900 million doses. The European Commission did not immediately confirm this detail to CNN.
A spokesperson for the European Commission would not comment on the details outlined in the New York Times report. Instead, CNN referred to von der Leyen’s speech on Friday, “she said in The speech talked about the importance of vaccine strategies for establishing effective relationships between the European Commission and the various stakeholders involved in our work.”
“[The contract] It will ensure that the dose required for the injection is strengthened to enhance our immunity to the virus. It will provide a vaccine suitable for evading variants that no longer respond to the vaccine. It should enable us to vaccinate children and adolescents when necessary and safe. It will consolidate Europe’s leading position in mRNA technology. “She said, referring to the technology used in Pfizer and Moderna vaccines.
The European Commission announced on Monday that it is filing a lawsuit against AstraZeneca, accusing it of violating the vaccine supply contract. The dispute over months of delay in delivery has escalated sharply, hindering the introduction of vaccines in most parts of Africa.
27 EU countries have ordered 300 million doses of Covid-19 vaccine from AstraZeneca, which are scheduled to be delivered by the end of June, and can choose to purchase another 100 million doses. However, the delivery of vaccines has repeatedly reduced millions of doses. The British-Swedish drugmaker said it will deliver 100 million doses by the end of June, which is one-third of its original contract with the European Union.
Outside the Brussels court, Hakim Boularbah, a lawyer representing AstraZeneca, said: “The only thing I can say is that AstraZeneca deeply regrets the European Commission’s decision to bring this lawsuit to court. . They hope that the dispute can be resolved as soon as possible. As much as possible.”
The company has repeatedly dismissed its allegations of breach of contract. Its chief executive, Pascal Soriot, emphasized in January that its contract was based on the company’s best efforts to deliver on time and that the goal was not legally binding.
The complete, unedited contract between the European Commission and AstraZeneca-first published by the Italian broadcaster RAI-contains a clause that appears to protect the company from legal action due to delayed deliveries. However, the court may decide whether the company has indeed made the “maximum reasonable effort” to achieve its objectives as stipulated in the contract.
The committee’s lawyer, Rafaël Jafferali, said outside the courtroom on Wednesday: “We presented our case in court. We explained the situation. Our comments are presented to the court.”
A court spokesperson told CNN that the European Union hopes the company will catch up with its deliveries to the European Union.
The next hearing is scheduled for May 26. The judge expects it will take three to six weeks to make a ruling.
Reports of rare but sometimes fatal blood coagulopathy after the use of this vaccine in young people (mainly women) have prompted some countries to restrict their vaccine to their older people.
AstraZeneca will release its first-quarter financial results on Friday.